In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on ADC Therapeutics (ADCT – Research Report), with a price target of $55.00. The company’s shares closed last Tuesday at $16.94, close to its 52-week low of $16.35.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of -18.3% and a 19.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Black Diamond Therapeutics, and Turning Point Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ADC Therapeutics with a $44.50 average price target.
Based on ADC Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $13.15 million and GAAP net loss of $71.55 million. In comparison, last year the company had a GAAP net loss of $20.33 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company’s product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
Read More on ADCT:
- Microsoft (MSFT) Received its Third Buy in a Row
- Analysts Are Bullish on These Healthcare Stocks: Turning Point Therapeutics (TPTX), Zynex (ZYXI)
- H.C. Wainwright Thinks Electrocore’s Stock is Going to Recover
- H.C. Wainwright Thinks Revance Therapeutics’ Stock is Going to Recover
- Vaccitech Plc (VACC) Gets a Buy Rating from H.C. Wainwright